Medline Exits All Medline Brand Beds; Field Action Costs Up to $220M
MDLN is trading near its 52-week low of $31.49 (12% above the low).
Summary
Medline is discontinuing and exiting all Medline Brand beds after a voluntary field action, with estimated costs of up to $220 million in 2026-2027 on about $60 million of annual sales. The company says fiscal 2026 guidance is unchanged.
Key Events · Legal and Risk Events · MDLN
-
Full Exit From Medline Brand Beds
A voluntary field action initiated October 14, 2026 removes, discontinues and exits all Medline Brand beds — homecare, bariatric and long-term care — plus pendants, accessories, replacement parts and bed-containing order packages.
-
Up to $220M in Estimated Costs
Inventory impairment, disposal and customer credits are estimated at up to $220 million, to be incurred in 2026 and 2027 and excluded from Adjusted EBITDA. The range reflects uncertainty over future customer participation.
-
Small Revenue Base Affected
Affected products generated approximately $60 million of net sales in the twelve months ended June 27, 2026 — a fraction of the $7.7 billion in quarterly sales reported for Q2 2026.
-
Guidance Reaffirmed for Fiscal 2026
Medline says it does not currently expect a material impact on fiscal 2026 results, including the full-year guidance provided August 5, 2026.
Analysis · MDLN · Industrial Applications And Services
Medline is pulling its entire Medline Brand bed line — homecare, bariatric and long-term care beds plus accessories — off the market in a voluntary field action started October 14. The products brought in only about $60 million of sales over the trailing twelve months, so the revenue loss is small, but the cleanup bill is not: up to $220 million of inventory impairment, disposal and customer credits across 2026 and 2027. Management says the costs will be excluded from Adjusted EBITDA and that fiscal 2026 guidance given August 5 still holds, which is the key claim to test — the charge is real cash and accounting cost even if it sits outside the adjusted metric. The wide range reflects uncertainty over how many customers take credits. This lands on top of an already rough stretch: a 13% share drop on October 6 over product quality issues, a securities fraud investigation, and roughly $880 million of insider selling in the last 90 days.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDLN was trading at $35.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $46.4B. The 52-week trading range was $31.49 to $50.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.